Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 2NET 1Endocrine 1

Conditions

Pheochromocytoma 2Neuroblastoma 2Pancreatic Neoplasms 1Neoplasm Metastasis 1Gastro-enteropancreatic neuroendocrine tumor 1Carcinoma, Islet Cell 1Adrenocortical Carcinoma 1

Interventions

Sunitinib 3Trastuzumab 2Temozolomide 2Magnetic Resonance Spectroscopy 2Capecitabine 2Bortezomib 2tovorafenib 1tipifarnib 1telotristat ethyl 1surufatinib 1sintilimab 1selpercatinib 1sargramostim 1romidepsin 1pasireotide 1milademetan 1lutetium Lu 177 dotatate 1gallium Ga 68 dotatate 1folfirinox 1fludarabine phosphate 1fludarabine 1entrectinib 1entinostat 1copper dotatate CU-64 1alectinib 1aldesleukin 1Topotecan 1Taxes 1TH 302 1Standard of Care 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pancreatic Neoplasms × Granulocyte Colony-Stimulating Factor × Endocrine × Clear all
NCT03042780 2020-11-27

FOLFIRINOX in Metastatic High Grade Gastroenteropancreatic Neuroendocrine Carcinomas

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Terminated
2 enrolled 6 charts
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Neoplasm Metastasis, Pancreatic Neoplasms, Carcinoma, Islet Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡